|
EP2156834A1
|
|
Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
|
|
EP2143422A1
|
|
Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
|
|
WO2010004594A1
|
|
Ophthalmic compositions for treating pathologies of the posterior segment of the eye
|
|
WO2009104045A1
|
|
Ophthalmic gemifloxacin compositions for the treatment of ocular infections
|
|
EP1075837A2
|
|
Process for the preparation of aqueous formulations for ophthalmic use
|
|
ITMI941184D0
|
|
Detergent, emollient and hydrating composition for use as an auxiliary in the hygienic treatment of blepharitis
|
|
EP0456988A2
|
|
Use of naproxen as mydriatic agent
|
|
EP0332946A1
|
|
The dipeptide L-pyroglutamyl-L-cysteine, having a high anti-cataractogenic activity, and pharmaceutical compositions containing the same
|
|
US4797423A
|
|
Lysine salt of 4-diphenylacetic acid and its ophthalmic fomulations
|
